Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
Drug Pricing Tomorrow: JPA’s Abe Eyes Longer-Term Trial for Key Pricing Premium
To read the full story
Related Article
- Drug Pricing Tomorrow: Full Interview with JMA Vice President Nakagawa
October 5, 2015
- Drug Pricing Tomorrow: JMA’s Nakagawa Says Price Maintenance Premium Should Continue as Trial Measure
September 29, 2015
- Drug Pricing Tomorrow: Full Interview with MOF Budget Examiner Unami
September 25, 2015
- Drug Pricing Tomorrow: Full Interview with MHLW Councilor Takeda - Part 2
September 10, 2015
- Drug Pricing Tomorrow: MOF Budget Examiner Eyes “Sharp Price Cuts” for Both New and Listed Generics in 2016
September 9, 2015
- Drug Pricing Tomorrow: Full Interview with MHLW Councilor Takeda - Part 1
September 9, 2015
- Drug Pricing Tomorrow: Full Interview with FPMAJ’s Kamoya - Part 2
September 8, 2015
- Drug Pricing Tomorrow: MHLW Councilor Takeda Says NHI Drug Prices Should Mirror Evaluation of Individual Firms
August 24, 2015
- Drug Pricing Tomorrow: Full Interview with FPMAJ’s Kamoya - Part 1
August 20, 2015
- Drug Pricing Tomorrow: Full Interview with JPA Executive Director Abe
August 13, 2015
- Drug Pricing Tomorrow: FPMAJ’s Kamoya Says Innovation Premium Meant to Head Off Future Drug Lags
August 10, 2015
- Drug Pricing Tomorrow: Full Interview with Kenporen Vice President Shirakawa
July 24, 2015
- Drug Pricing Tomorrow: Kenporen Veep Wants Holistic Drug Policy in FY2016 Reform
July 15, 2015
- Drug Pricing Tomorrow: Full Interview with MHLW Economic Affairs Head Jo - Part 2
July 15, 2015
- Drug Pricing Tomorrow: Full Interview with MHLW Economic Affairs Head Jo - Part 1
July 8, 2015
- Drug Pricing Tomorrow: Full Interview with Ex-Chuikyo Chairman Endo
July 2, 2015
- Drug Pricing Tomorrow: MHLW’s Jo Says Price-Maintenance Premium Crucial as Post-Launch Reward for Innovation
June 29, 2015
- Drug Pricing Tomorrow: Ex-Chuikyo Chair Urges Pharma to Look at How to Refine Premium, Not Permanent Introduction
June 25, 2015
ORGANIZATION
- New Task Force Discussing Steps to Stem Further Increase in Drug Lag/Loss: JPMA
April 30, 2024
- JPMA Eager to Work with Regulators to Improve Guidance on Orphan Meds, PI Trials
April 30, 2024
- Policymakers Prod for Industry’s Concrete Actions Toward Eliminating Drug Loss
April 24, 2024
- Govt Should Buy Up Domestic Antibiotic APIs, Cost 5-8 Times Higher: Industry Official
April 24, 2024
- JPMA Reiterates Opposition to Off-Year Revisions towards Honebuto 2024
April 19, 2024
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…